2026 Interim Report
Filed with HKEX · Stock code 6622 · · 118 pages · English and Chinese
Corporation Information 公司資料 Financial Summary 財務概要 Chairman and CEO Statement 主席兼行政總裁報告 Management Discussion and Analysis 管理層討論及分析 Overview 概覽 Business Review 業務回顧 Financial Review 財務回顧 Other Information 其他資料 Consolidated Statement of Profit or Loss 綜合損益表 Consolidated Statement of Profit or Loss and Other Comprehensive Income 77 综合損益及其他全面收益表 Consolidated Statement of Financial Position 综合財務狀況表 7
Zhaoke Ophthalmology Ltd. on 6ix
Earlier from Zhaoke Ophthalmology
- Notification letter to registered shareholders and reply form
- Notification letter to non-registered shareholders and reply form
- Zhaoke Ophthalmology Announces 2022 Interim Results
- Two Products of Zhaoke Ophthalmology (6622.HK) Passed The On-Site Inspection for Drug Registration of The National Medical Products Administration and The GMP Compliance Inspection of The Guangdong Medical Products Administration
Later from Zhaoke Ophthalmology
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Next Day Disclosure Return
- (Revised) Next Day Disclosure Return (Amendment for the return on 15 October November 2026)
- (Revised) Next Day Disclosure Return (Amendment for the return on 16 October November 2026)
Follow Zhaoke Ophthalmology into a list and get an email when it puts out news.
Follow Zhaoke Ophthalmology